Amylin and GLP-1 Synergy
By April 10, 2026, the FDA decision for CagriSema—a combination of semaglutide and cagrilintide—is imminent. This dual-attack on hunger targets the brain and stomach, promising results previously only seen with surgery.
Strategic Data Expansion 2026.4
The 25% Threshold
Trials show massive body weight reduction and glycemic stability. LSI keywords like 'amylin mimetics' and 'Redefine 1 trial' are now high-priority.
Synergistic Potency Formula
Synergistic Effect Ratio
$$E_{total} > E_{GLP ext{-}1} + E_{Amylin}$$
Strategic Advice: Consider CagriSema if you have plateaued on standard GLP-1 therapy.